Opus Genetics, Inc.

IRD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-25.3M $-9.3M $-14.4M $-18.5M $-9.5M $-6.2M $-11.3M $-14.0M
Depreciation & Amortization $42.4K $32.9K $27.5K $28.3K $37.1K $42.4K $45.1K $50.7K
Depreciation $28.3K $37.1K $42.4K $45.1K
Amortization
Stock-Based Compensation $1.0M $1.4M $1.0M $608.8K $565.4K $231.0K $638.6K $584.7K
Net Cash from Operating Activities $-15.4M $-13.2M $-17.4M $-11.0M $-8.0M $-6.6M $-15.5M $-7.0M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $-9.4M $845.5K $2.2M $-545.9K $-660.0K
Financing Activities
Dividends Paid
Stock Repurchases $0 $0
Net Cash from Financing Activities $22.1M $12.3M $8.1M $13.6M $12.7M
Net Change in Cash $-2.7M $1.4M $373.2K $-8.9M $5.2M $3.6M $-2.5M $5.0M
Free Cash Flow
← Newer Page 2 of 3 Older →